Gerardo Antonio Umanzor Funez, MD, on Metastatic Breast Cancer: Comparing IV and Oral Formulations of Paclitaxel
2019 San Antonio Breast Cancer Symposium
Gerardo Antonio Umanzor Funez, MD, of Liga Contra El Cáncer, discusses phase III findings on intravenous (IV) paclitaxel and oral paclitaxel plus encequidar (a novel P-gp inhibitor), the first orally administered taxane regimen shown to be superior to the IV formulation in terms of response and survival with less neuropathy (Abstract GS6-01).
Jack Cuzick, PhD, of Queen Mary University of London, discusses the substantially greater benefits of anastrozole as compared with tamoxifen in terms of preventing breast cancer, with no increase in fractures or other reported serious side effects (Abstract GS4-04).
Marie-Jeanne T.F.D. Vrancken Peeters, MD, PhD, of the Netherlands Cancer Institute, discusses an interim study analysis showing that ultrasound-guided core biopsies of the breast in patients with excellent response on MRI after neoadjuvant systemic therapy may not be accurate enough to safely select patients with pathologic complete response for omission of surgery (Abstract GS5-06).
Rashmi K. Murthy, MD, of The University of Texas MD Anderson Cancer Center, discusses data on the efficacy and safety of tucatinib, trastuzumab, and capecitabine, a treatment regimen under investigation for patients with advanced HER2-positive metastatic breast cancer refractory to standard-of-care regimens (Abstract GS1-01).
Priyanka Sharma, MD, of the University of Kansas Medical Center, reviews new phase III data on adding oral fluoropyrimidine to adjuvant endocrine therapy, the current standard of care, in the setting of hormone receptor–positive, HER2-negative primary breast cancer (Abstract GS1-09).
Ariella B. Hanker, PhD, of UT Southwestern Medical Center, discusses data showing that breast cancers expressing co-occurring HER2 and HER3 mutations may require the addition of a phosphoinositide 3-kinase alpha inhibitor to a HER2 tyrosine kinase inhibitor (Abstract GS6-04).
